These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Neuropharmacology of the anxiolytic drug opipramol, a sigma site ligand. Müller WE; Siebert B; Holoubek G; Gentsch C Pharmacopsychiatry; 2004 Nov; 37 Suppl 3():S189-97. PubMed ID: 15547785 [TBL] [Abstract][Full Text] [Related]
6. Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression. Wesołowska A; Nikiforuk A; Stachowicz K; Tatarczyńska E Neuropharmacology; 2006 Sep; 51(3):578-86. PubMed ID: 16828124 [TBL] [Abstract][Full Text] [Related]
7. Open trial study of a combined antidepressant (amitryptiline, perphenazine, diazepam) versus fluoxetine or imipramine in ambulatory depressed patients. Diaz A; Fouilloux C; Ortiz S Proc West Pharmacol Soc; 2002; 45():154-5. PubMed ID: 12434564 [No Abstract] [Full Text] [Related]
8. Effects of a selective 5-HT1B receptor agonist and antagonists in animal models of anxiety and depression. Tatarczyńska E; Kłodzińska A; Stachowicz K; Chojnacka-Wójcik E Behav Pharmacol; 2004 Dec; 15(8):523-34. PubMed ID: 15577451 [TBL] [Abstract][Full Text] [Related]
10. Does rat global transient cerebral ischemia serve as an appropriate model to study emotional disturbances? Bantsiele GB; Bentué-Ferrer D; Amiot N; Allain H; Bourin M; Reymann JM Fundam Clin Pharmacol; 2004 Dec; 18(6):685-92. PubMed ID: 15548240 [TBL] [Abstract][Full Text] [Related]
11. Modern indications for the use of opipramol. Krysta K; Murawiec S; Warchala A; Zawada K; Cubała WJ; Wiglusz MS; Jakuszkowiak-Wojten K; Krzystanek M; Krupka-Matuszczyk I Psychiatr Danub; 2015 Sep; 27 Suppl 1():S435-7. PubMed ID: 26417811 [TBL] [Abstract][Full Text] [Related]
12. Antidepressant-like properties of some serotonin receptor ligands and calcium channel antagonists measured with the forced swimming test in mice. Biała G Pol J Pharmacol; 1998; 50(2):117-24. PubMed ID: 9798263 [TBL] [Abstract][Full Text] [Related]
13. Recognition of depressive syndromes, tricyclics, and the second generation antidepressants. Tollefson G; Tuason VB Minn Med; 1984 Jun; 67(6):345-50. PubMed ID: 6147748 [No Abstract] [Full Text] [Related]
15. Specific modulation of sigma binding sites by the anxiolytic drug opipramol. Holoubek G; Müller WE J Neural Transm (Vienna); 2003 Oct; 110(10):1169-79. PubMed ID: 14523629 [TBL] [Abstract][Full Text] [Related]
17. [Therapy with antidepressive and tranquilizing agents]. Barocka A Fortschr Med; 1984 Aug; 102(31-32):775-9. PubMed ID: 6148296 [TBL] [Abstract][Full Text] [Related]
18. [Use of benzodiazepines in the treatment of depression]. Escande M; Granier F; Girard M Encephale; 1983; 9(4 Suppl 2):273B-277B. PubMed ID: 6144524 [TBL] [Abstract][Full Text] [Related]
19. New findings in anxiety. A synthesis for clinical practice in 1985. Curtis GC Psychiatr Clin North Am; 1985 Mar; 8(1):169-75. PubMed ID: 2859578 [TBL] [Abstract][Full Text] [Related]
20. Lack of advantage for imipramine combined with lithium versus imipramine alone in the treatment of major depression--a double-blind controlled study. Shahal B; Piel E; Mecz L; Kremer I; Klein E Biol Psychiatry; 1996 Dec; 40(11):1181-3. PubMed ID: 8931923 [No Abstract] [Full Text] [Related] [Next] [New Search]